Home > Sample essays > What is Influenza? History, Clinical Presentation, and Treatment Recommendations

Essay: What is Influenza? History, Clinical Presentation, and Treatment Recommendations

Essay details and download:

  • Subject area(s): Sample essays
  • Reading time: 3 minutes
  • Price: Free download
  • Published: 1 April 2019*
  • Last Modified: 23 July 2024
  • File format: Text
  • Words: 761 (approx)
  • Number of pages: 4 (approx)

Text preview of this essay:

This page of the essay has 761 words.



What is influenza?

“Contagious respiratory illness caused by influenza viruses that infect the nose, throat, and lungs”1

 

 History of Influenza5

● Flu pandemic of 1918 to 1919 infected about 500 million people worldwide and killed 20 to 50 million.

● In the U.S., more than 25% of Americans became sick, and 675,000 Americans died.

● Pandemic caused by flu virus that had invaded lungs and caused pneumonia.

● AKA Spanish flu

 

 Clinical Presentation

● Systemic

○ Fever, chills, headache, myalgia,

malaise, anorexia ● Respiratory

○ Cough, severe pharyngeal pain, nasal obstruction and discharge

● Complications

○ Viral pneumonia, secondary bacterial

pneumonia

    urgentcareatlanta.com

 Influenza Virus

● Family

○ Orthomyxoviridae

● Type of Nucleic Acid

○ 6-8 SS (-) RNA segments

● Genome Size ○ 10-15 kb

micro.magnet.fsu.edu

    

 Influenza Viruses

● Classification

○ Influenza A, B, C

● Epidemiology

○ U.S. mortality can be as high as 51,000

● Pathogenesis

○ Respiratory droplets and aerosols

○ Presentation of symptoms in 1-2 days

● Diagnosis

○ Nose and throat swab specimens

○ Viral antigen detection

○ Serologic tests

techtreme.com

    

 Classification

● Influenza A

○ Humans, birds, pigs, horses, marine mammals

○ Divided according to hemagglutinin and neuraminidase subtype

● Influenza B

○ Humans only

○ Not classified to subtype

● Influenza C

○ Humans only; mild illness

○ Not classified to subtype

 

 Anti-Influenza Agents- Neuraminidase Inhibitors

   Drugs

MOA

Other Info

● oseltamivir (Tamiflu) (PO)

● zanamivir (Relenza) (inhalation)

● peramivir (Rapivab) (IV)

Competitively and reversibly interacts with the active enzyme (sialic acid) to inhibit viral neuraminidase activity

● Vast majority of circulating viruses are susceptible to these agents

● Oseltamivir or zanamivir = for

patients with confirmed or suspect influenza who have severe, complicated, or progressive illness

 

 Anti-Influenza Agents- M2 Inhibitors

   Drugs

MOA

Other Info

● amantadine (Symmetrel) (PO)

● rimantadine (Flumadine) (PO)

block the M2 proton ion channel of the virus particle and inhibits uncoating of the viral RNA within infected host cells, which prevents replication

● Not recommended for treatment or

prophylaxis of influenza A due to resistance

● Not effective against influenza B

 

 Treatment of Influenza2

● Subset of patients with confirmed or suspected influenza who require treatment

within 24 hours – 48 hours MAX ○ Hospitalized

○ Severe, complicated, or progressive illness (e.g., post-flu pneumonia)

○ Patients at higher risk for influenza complications

■ Children < 2 years or adults > 65 years

■ Those with chronic pulmonary, CV, renal hepatic, hematological, metabolic, or neurologic

disorders, stroke, or intellectual disability

■ Immunosuppressed

■ Pregnant or postpartum

■ Morbidly obese

■ Residents of nursing homes or other chronic-care facilities

■ American Indians/Alaska Natives

 

  Treatment Recommendations3

● oseltamivir (Tamiflu)

○ Influenza A and B; oral only

○ Treatment: Any age

○ Chemoprophylaxis: 3 months and older

○ AEs:

■ Nausea, vomiting, serious skin reactions and sporadic, transient neuropsychiatric events (self-injury or delirium); mainly reported among Japanese adolescents and adults)

● peramivir (Rapivab)

○ Influenza A and B; IV only

○ Treatment: 18 years and older

○ Chemoprophylaxis: N/A

○ AEs:

■ Diarrhea, postmarketing reports of serious skin reactions and sporadic, transient neuropsychiatric events (self-injury or delirium; mainly reported among Japanese adolescents and adults)

natcopharma.co.in

   

 Treatment Recommendations3

● zanamivir (Relenza)

○ Influenza A and B; inhalation only

○ Treatment: 7 years and older

○ Chemoprophylaxis: 5 years and older

○ Not recommended for use in people with underlying

respiratory diseases (e.g., asthma, COPD)

○ AEs

■ Diarrhea, nausea, sinusitis, nasal signs and symptoms, bronchitis, cough, headache, dizziness, and ear, nose and throat infections

    drugs.com

 Prevention1,2

● Stay away from sick people

● Stay home if you’re sick

● Cover coughs and sneezes

● Avoid touching your eyes, nose, or mouth

● Proper hand washing techniques

● Receive annual flu vaccination

    http://www.health.state.mn.us

 Prevention – Vaccinations1,2

Inactivated

● Trivalent

○ Virus grown in eggs (ask about egg

allergy before administration)

○ > 65 y/o: high-dose

● Quadrivalent

○ Virus grown in cell culture

Live-Attenuated

● FluMist

● Administered intranasally

● Not approved for 2016-2017 season

   

 Fast Facts2

● How does the vaccine work?

○ Antibodies develop in the body 2 weeks after

administration

○ These antibodies provide protection against the

viruses in the vaccine

● Who should get vaccinated?

○ Everyone 6 months of age and older ● When is flu season?

○ October – May

● Why get the vaccine every year?

○ Flu viruses are always changing

● Does the flu vaccine cause the flu? ○ NO!

blogs.scientificamerican.com

    

 2016-2017 Flu Season

● Three-component vaccines are recommended to contain:

○ A/California/7/2009 (H1N1)pdm09-like virus

○ A/Hong Kong/4801/2014 (H3N2)-like virus and a

○ B/Brisbane/60/2008-like virus (B/Victoria lineage).

● Four component vaccines = the same three viruses above + additional B virus called B/Phuket/3073/2013-like virus (B/Yamagata lineage)

● Live attenuated influenza vaccine or nasal spray are not recommended for use during 2016-2017 season because of concerns about its effectiveness

 

  4

  4

  4

2016-2017 Flu Season Synopsis4

● Most frequently identified influenza virus subtype reported was influenza A (H3).

● Proportion of deaths caused by pneumonia and influenza was reported to be above epidemic threshold.

● Five pediatric deaths caused by influenza.

● 46.9 hospitalizations per 100,000 caused by influenza.

● Outpatient visits for influenza-like illness was 3.7% (above national

baseline of 2.2%).

● 36 states reported influenza as widespread.

 

About this essay:

If you use part of this page in your own work, you need to provide a citation, as follows:

Essay Sauce, What is Influenza? History, Clinical Presentation, and Treatment Recommendations. Available from:<https://www.essaysauce.com/sample-essays/2018-4-7-1523122015-2/> [Accessed 16-04-26].

These Sample essays have been submitted to us by students in order to help you with your studies.

* This essay may have been previously published on EssaySauce.com and/or Essay.uk.com at an earlier date than indicated.